Brokerages Anticipate Merus NV (MRUS) to Post -$0.52 EPS
Wall Street analysts expect Merus NV (NASDAQ:MRUS) to announce earnings of ($0.52) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Merus’ earnings. The lowest EPS estimate is ($0.57) and the highest is ($0.47). Merus reported earnings per share of ($0.49) during the same quarter last year, which would suggest a negative year-over-year growth rate of 6.1%. The company is expected to issue its next earnings results on Thursday, July 25th.
According to Zacks, analysts expect that Merus will report full-year earnings of ($2.52) per share for the current financial year, with EPS estimates ranging from ($2.58) to ($2.45). For the next financial year, analysts expect that the company will post earnings of ($2.33) per share, with EPS estimates ranging from ($3.06) to ($1.60). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Merus.
Merus (NASDAQ:MRUS) last released its quarterly earnings results on Wednesday, April 3rd. The biotechnology company reported ($0.34) earnings per share for the quarter. The firm had revenue of $9.67 million during the quarter. Merus had a negative return on equity of 40.84% and a negative net margin of 77.61%.
Hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. purchased a new stake in Merus in the 1st quarter valued at approximately $79,000. BlackRock Inc. purchased a new stake in Merus in the 1st quarter valued at approximately $131,000. Squarepoint Ops LLC lifted its stake in Merus by 10.3% in the 4th quarter. Squarepoint Ops LLC now owns 11,800 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 1,100 shares in the last quarter. Geode Capital Management LLC lifted its stake in Merus by 18.8% in the 4th quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 2,373 shares in the last quarter. Finally, Granite Investment Partners LLC purchased a new stake in Merus in the 1st quarter valued at approximately $468,000. 53.06% of the stock is currently owned by hedge funds and other institutional investors.
Shares of MRUS traded up $0.52 on Thursday, reaching $14.14. The stock had a trading volume of 2,442 shares, compared to its average volume of 31,210. The stock has a market cap of $314.65 million, a P/E ratio of -7.68 and a beta of -0.05. Merus has a twelve month low of $11.00 and a twelve month high of $26.74.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Read More: Total Return
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.